Review your medical history, including pancreatitis, gallbladder disease, kidney issues, thyroid cancer history, pregnancy plans, diabetes medicines, and prior reactions to injectable therapies
2 Since it is non-peptide, orforglipron avoids GI degradation barriers that limit peptides, thereby enabling once-daily administration while maintaining efficacy on glucose control, body weight, and tolerability
Some patients run BPC-157, a GLP-1 medication, and additional peptides (such as TB-500 for enhanced tissue repair)
VEGFR2 study remains one of the most-cited mechanistic papers on this peptide
Dont inject into muscles, veins, or scars, and dont use areas of skin that are red, bruised, or cut